Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Alemtuzumab Dosing for Allogeneic HCT in Non-Malignant Diseases
NCT05501756Phase 2Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jan 2023
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in Allogeneic hematopoietic cell transplantation (allo-HCT), sponsored by Cincinnati Children's Hospital Medical Center. Started Jan 2023; status: recruiting.
02
Drugs
alemtuzumab
03
Conditions
Allogeneic hematopoietic cell transplantation (allo-HCT)
Beyond the preview
Go deeper on NCT05501756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501756.